MedTrace Logo

CoQ10 Biomarker Trial

NCT01408680 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2014-12-04

No results posted yet for this study

Summary

The investigators believe that relieving the oxidative stress experienced by hemodialysis patients may help improve cardiovascular health.

In this study, the investigators hypothesize that administration of coenzyme Q10, as a targeted antioxidant therapy, will ameliorate the excessive oxidative stress experienced by hemodialysis patients. This will lead to improvements in biomarkers of:

* oxidative stress status
* inflammatory status
* endothelial dysfunction

Conditions

Interventions

DIETARY_SUPPLEMENT

Coenzyme Q10

Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.

DIETARY_SUPPLEMENT

Coenzyme Q10

Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.

DIETARY_SUPPLEMENT

Placebo

Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.

Sponsors & Collaborators

Principal Investigators

  • Jonathan Himmelfarb, MD · University of Washington, Kidney Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-10-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01408680 on ClinicalTrials.gov